Sensitivity of Hartmannella (Acanthamoeba) to 5-Fluorocytosine, Hydroxystilbamidine, and Other Substances

Total Page:16

File Type:pdf, Size:1020Kb

Sensitivity of Hartmannella (Acanthamoeba) to 5-Fluorocytosine, Hydroxystilbamidine, and Other Substances J. clin. Path., 1970, 23, 649-652 J Clin Pathol: first published as 10.1136/jcp.23.8.649 on 1 November 1970. Downloaded from Sensitivity of Hartmannella (Acanthamoeba) to 5-fluorocytosine, hydroxystilbamidine, and other substances DAVID P. CASEMORE From the Department of Virology, Public Health Laboratory, Middlesbrough, Teesside SYNOPSIS The effect of 24 anti-amoebic and other chemotherapeutic compounds on six strains of hartmannellid amoebae was studied by tissue culture, agar diffusion, and liquid axenic culture. Ofthe recognized anti-amoebic compounds only one inhibited growth of the amoebae, which were remarkable for their resistance. Two compounds, hydroxystilbamidine isethionate and 5-fluorocytosine, showed somecopyright. amoebicidal activity while some others were inhibitory. http://jcp.bmj.com/ Hartmannella and Naegleria have both been Materials and Methods reported as causes of primary amoebic meningo- encephalitis but recent reports on the role of normally saprophytic amoebae in human disease AMOEBAE have tended to emphasize Naegleria as the chief Six strains ofamoebae were used. They conformed potential pathogen (eg, Carter, 1968; Apley, to Warhurst and Armstrong's description (1968) Clarke, Roome, Sandry, Saygi, Silk, and War- of Hartmannella castellanii. Their sources are on September 28, 2021 by guest. Protected hurst, 1970). However, the ability of some shown in Table I. hartmannellae to grow at 33-37'C, to produce degenerative changes in tissue culture, and to produce a lethal meningo-encephalitis in small Strain Number and Origin Source laboratory mammals suggests that they should as as pro- 29 Manchester Postmortem bronchial swab be regarded facultatively pathogenic, 324 Cirencester Throat swab posed by Griffin and others (Armed Forces B147 London Throat swab Institute of Pathology, 1968). 565 Leeds Throat swab 524 Coventry Throat swab The taxonomy of the hartmannellid group has M67 Middlesbrough Tissue culture contaminant not yet been resolved. Page (1967a and b, and personal communication) would give the amoebae Table I Sources ofamoebae and geographical used in this study the generic status Acantha- origins moeba: I do not feel competent to judge this point and have retained the nomenclature previously used. The potentially pathogenic COMPOUNDS UNDER TEST nature of some hartmannellid amoebae suggested Compounds were chosen because they had re- that an examination oftheir drug sensitivity would puted antiprotozoal activity, because they were be worthwhile. chemically related to known antiprotozoal agents, Received for publication 30 April 1970. because they were constituents of tissue-culture 650 David P. Casemore J Clin Pathol: first published as 10.1136/jcp.23.8.649 on 1 November 1970. Downloaded from media that might be used for attempts at iso- EXAMINATION lation of amoebae, or because their mode of Although growth could often be detected by action against other organisms suggested possible naked-eye examination, especially in PPG activity against amoebae. medium, all cultures were examined micro- Some compounds used for the treatment of scopically after 24 hours and then at irregular entamoebiasis were not tested in this study in intervals during the week after inoculation. Tests vitro because they depend for their activity on a were controlled by inoculating each strain, in chemical reaction within the intestinal tract, parallel with the test, into the same medium free resulting in the local release of iodine, arsenic, from the compound under test. Results were etc. recorded as heavy, moderate, or scanty growth, Compounds were obtained as pure powders growth not detected, and, when marked differen- from the makers, or as pharmaceutical prepa- ces occurred,approximate proportions of cysts to rations for injection. Stock solutions were pre- trophozoites. Equivocal results, especially those pared, usually in distilled water, at a concentration involving few survivors after exposure to in- of 1,000 ,jg/ml. Each was tested for anti-amoebic hibitory compounds, were checked by recovering activity at an arbitrary concentration of 100 pkg/ the amoebae and subculturing to assess their ml. Compounds showing some effect at this viability. concentration were tested by titration in at least two of the test systems used; those showing no effect or only slight inhibition at 100 ,ug/ml by all INTERPRETATION three methods were not tested further. The relative amounts of growth recorded for tests and controls were interpreted as follows: TISSUE CULTURE 1 No effect HeLa cells were grown and maintained using When test and control showed no difference in conventional media and methods. Sensitivity rate of multiplication, yield of trophozoites, or tests were performed in media without any of the rate of encystment. antibiotics normally used to control bacterial and mycotic growth. 2 Inhibition without amoebicidal effect copyright. When any of the following effects were noted in test cultures: (a) slower rate of multiplication, AGAR DIFFUSION (b) lower yield of trophozoites, or (c) more rapid Klebsiella-water-agar medium (Warhurst and encystment. Armstrong, 1968) was used; 1 ml of the tenfold concentration of the compound being tested was 3 Amoebicidal effect mixed with 9 ml of cooled, molten agar. Killed When (a) cysts recovered from (2) failed to Klebsiella was used to avoid inconsistencies that vegetate in medium free from the compoundhttp://jcp.bmj.com/ might arise when the Klebsiella was itself in- being tested, or (b) when the addition of a test hibited by the compound under test. compound to a dense, actively growing axenic culture of trophozoites caused loss of viability as indicated by subculture of trophozoites to fresh AXENIC CULTURE medium free from the compound being tested. Several peptone media, with and without glucose, were tried (Neff, 1957; Adam, 1964). Best growth on September 28, 2021 by guest. Protected was obtained in a thin layerof medium containing 4% proteose-peptone (Difco) and 1 % glucose, Results dissolved in tap water and sterilized by auto- claving (PPG medium). Table II shows the results ofpreliminary screening In most cases a tenfold concentration of the of the test substances or combinations at as compound was diluted with the medium and concentration of 100 ,ug/ml of each compound. then inoculated with the amoebae. In some cases, Only four substances, amphotericin B, paromo- however, the compound was added to a dense, mycin, hydroxystilbamidine isethionate, and actively growing culture. 5-fluorocytosine, were sufficiently active in the Tests for combined drug action were performed screening tests to justify further studies. The using chess-board titrations to give varying purpose of the study was to investigate the sensi- concentration ratios in PPG medium in a divided tivity pattern rather than to determine minimum Petri dish (Sneath and Stevens, 1967). inhibitory concentrations (MICs). Although the strains of amoebae showed slight differences in their growth characteristics and MICs there was INCUBATION no difference in their sensitivity patterns, so drug! All cultures were incubated at 37°C. Proteose- effects on the six strains are not shown separately. peptone glucose and agar-culture containers were Antimetabolites acting on the folic acid cycle- enclosed in polythene bags to reduce evaporation. sulphonamides, trimethoprim, pyrimethamine- to andothersubstances 651 SensitivityofHartmannella(Acanthamoeba) 5-fluorocytosine, hydroxystilbamidine, J Clin Pathol: first published as 10.1136/jcp.23.8.649 on 1 November 1970. Downloaded from tend to act synergistically. Different sulphon- each at concentrations of 100, 80, 60, 40, and 20 amides may vary in their efficacy to potentiate ,g/ml, failed to show any potentiation of the other substances acting on the folic acid cycle or inhibition indicated by the screen tests (Table II). in their suitability for use in this way. In any such Sulphadiazine by itself was only feebly in- combination the degree of potentiation may be hibitory against all the strains. However, Dr C. affected by the ratio of compounds used. Chess- G. Cuthbertson (personal communication) found board titrations of trimethoprim/sulphamethox- it to be effective in mouse protection tests with azole and pyrimethamine/sulphormethoxine, Hartmannella strains that he tested. Amphotericin B was shown by Carter (1969), in laboratory studies, to be effective against Naegleria at a concentration of 0-075 ug/ml. In Compound Effect on Amoebae at mytests(TableIl)it was inhibitorytoHartmannel- 100 ,ug/ml' la at 10 ,ug/ml, but during prolonged incubation, Acetarsol No effect which causes inactivation of the drug, survivors Diloxanide furoate No effect multiplied vigorously. The effect was greater than Oxytetracycline No effect Benzyl penicillin No effect could be explained by the effect of the bile salt Streptomycin sulphate No effect incorporated with the drug to effect solution. Neomycin No effect Kanamycin No effect Paromomycin, an aminoglycoside of the Paromomycin I (marked) neomycin group, is effective against Entamoeba Chloroquin Morphological changes only had a marked Nystatin No effect histolytica. Although it inhibitory Metronidazole VI effect on Hartmannella, the surviving amoebae Polymyxin B I (feeble) were viable and multiplied rapidly when sub- Sulphonamides' VI Trimethoprim lactate No effect cultured to medium free from paromomycin. Pyrimethamine sulphate No effect Hydroxystilbamidine isethionate is a diamidine Trimethoprim + sulphamethoxazole I Trimethoprim + polymyxin
Recommended publications
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Acetarsol/Atovaquone 829 Effects on the Pancreas
    Acetarsol/Atovaquone 829 Effects on the pancreas. Pancreatitis has been associated with tavalent antimony 20 mg/kg daily for a minimum of 1-3 sodium stibogluconate treatment. Withdrawing treatment usu- 4 weeks is indicated. Similar doses are required for ally resulted in resolution of pancreatitis. Cl diffuse cutaneous leishmaniasis due to L. amazon- 1. Donovan KL, et al. Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment ensis and are continued for several months after clin- in a renal transplant recipient. J Infect 1990; 21: 107–10. ical improvement occurs. Relapses should be ex- O 2. Gasser RA, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; pected until immunity develops. 18: 83–90. 3. Domingo P, et al. Treatment of Indian kala-azar with pentavalent •In mucocutaneous leishmaniasis, daily doses of in- antimony. Lancet 1995; 345: 584–5. tramuscular pentavalent antimony 20 mg/kg are giv- en for a minimum of 4 weeks; if the response is poor, OH Pharmacokinetics 10 to 15 mg/kg may be given every 12 hours for the O The pentavalent antimony compounds are poorly ab- same period. Relapses are well known and have gen- sorbed from the gastrointestinal tract. After intrave- erally been associated with inadequate or interrupted Pharmacopoeias. In US. nous doses an initial distribution phase is followed by USP 31 (Atovaquone). A yellow powder. Insoluble in water; treatment; they are treated with the same drug given biexponential elimination by the kidneys. The elimina- slightly soluble in alcohol, in butanediol, in ethyl acetate, in gly- tion half-life of the initial phase is about 1.7 hours and for at least twice as long as the original treatment.
    [Show full text]
  • Drug Resistance in the Sexually Transmitted Protozoan Trichomonas Vaginalis
    Cell Research (2003); 13(4):239-249 http://www.cell-research.com Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis 1, 2 1 1 2 REBECCA L DUNNE , LINDA A DUNN , PETER UPCROFT , PETER J O'DONOGHUE , JACQUELINE A UPCROFT1,* 1 The Queensland Institute of Medical Research; The Australian Centre for International and TropicalHealth and Nutrition; Brisbane, Queensland 4029, Australia 2 The School of Molecular and Microbial Science, University of Queensland, Brisbane, Queensland 4072, Australia ABSTRACT Trichomoniasis is the most common, sexually transmitted infection. It is caused by the flagellated protozoan parasite Trichomonas vaginalis. Symptoms include vaginitis and infections have been associated with preterm delivery, low birth weight and increased infant mortality, as well as predisposing to HIV/AIDS and cervical cancer. Trichomoniasis has the highest prevalence and incidence of any sexually transmitted infection. The 5- nitroimidazole drugs, of which metronidazole is the most prescribed, are the only approved, effective drugs to treat trichomoniasis. Resistance against metronidazole is frequently reported and cross-resistance among the family of 5-nitroimidazole drugs is common, leaving no alternative for treatment, with some cases remaining unresolved. The mechanism of metronidazole resistance in T. vaginalis from treatment failures is not well understood, unlike resistance which is developed in the laboratory under increasing metronidazole pressure. In the latter situation, hydrogenosomal function which is involved in activation of the prodrug, metronidazole, is down-regulated. Reversion to sensitivity is incomplete after removal of drug pressure in the highly resistant parasites while clinically resistant strains, so far analysed, maintain their resistance levels in the absence of drug pressure.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom Et Al
    USOO8383154B2 (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom et al. (45) Date of Patent: Feb. 26, 2013 (54) SWELLABLE DOSAGE FORM COMPRISING W W 2.3. A. 3. 2. GELLAN GUMI WO WOO1,76610 10, 2001 WO WOO2,46571 A2 6, 2002 (75) Inventors: Daniel Bar-Shalom, Kokkedal (DK); WO WO O2/49571 A2 6, 2002 Lillian Slot, Virum (DK); Gina Fischer, WO WO 03/043638 A1 5, 2003 yerlosea (DK), Pernille Heyrup WO WO 2004/096906 A1 11, 2004 Hemmingsen, Bagsvaerd (DK) WO WO 2005/007074 1, 2005 WO WO 2005/007074 A 1, 2005 (73) Assignee: Egalet A/S, Vaerlose (DK) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 JECFA, “Gellangum”. FNP 52 Addendum 4 (1996).* U.S.C. 154(b) by 1259 days. JECFA, “Talc”, FNP 52 Addendum 1 (1992).* Alterna LLC, “ElixSure, Allergy Formula', description and label (21) Appl. No.: 111596,123 directions, online (Feb. 6, 2007). Hagerström, H., “Polymer gels as pharmaceutical dosage forms'. (22) PCT Filed: May 11, 2005 comprehensive Summaries of Uppsala dissertations from the faculty of pharmacy, vol. 293 Uppsala (2003). (86). PCT No.: PCT/DK2OOS/OOO317 Lin, “Gellan Gum', U.S. Food and Drug Administration, www. inchem.org, online (Jan. 17, 2005). S371 (c)(1), Miyazaki, S., et al., “In situ-gelling gellan formulations as vehicles (2), (4) Date: Aug. 14, 2007 for oral drug delivery”. J. Control Release, vol. 60, pp. 287-295 (1999). (87) PCT Pub. No.: WO2005/107713 Rowe, Raymond C.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]